Literature DB >> 23541808

[Intraabdominal desmoid tumors in familial adenomatous polyposis].

Paula Galletto1, Maria Liz Leoz, Antoni Castells, Francesc Balaguer.   

Abstract

Desmoid tumors are currently the main cause of morbidity and mortality in patients with familial adenomatous polyposis. More than 10% of these patients will develop these tumors during their lifetime and more than a third will suffer their consequences. The main risk factors for their development are female sex and abdominal surgery. The most frequent localization is intraabdominal. The therapeutic approach to these tumors has changed, and the surgical treatment of choice is currently the subject of debate. If a watch and wait approach is adopted, more than 50% of tumors will prove to be indolent. Therefore, the therapeutic strategy should be based on clinical presentation and should be decided by a multidisciplinary team working in a center with experience of these tumors. The present article proposes a prognostic classification to guide the therapeutic approach.
Copyright © 2012 Elsevier España, S.L. and AEEH y AEG. All rights reserved.

Entities:  

Keywords:  Aggresive fibromatosis; Colorectal cancer; Cáncer colorrectal; Desmoid tumor; Familial adenomatous polyposis; Fibromatosis agresiva; Poliposis adenomatosa familiar; Tumor desmoide

Mesh:

Substances:

Year:  2013        PMID: 23541808     DOI: 10.1016/j.gastrohep.2012.12.005

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  2 in total

1.  Transverse colonic volvulus due to mesenteric fibromatosis: a case report.

Authors:  Akihiro Yoshida; Yasutake Uchima; Naoki Hosaka; Kosuke Minaga; Masatoshi Kudo
Journal:  BMC Gastroenterol       Date:  2021-01-06       Impact factor: 3.067

2.  Mesenteric fibromatosis misdiagnosed with lymph node metastasis after successful laparoscopic right hemicolectomy: a report of two cases with review of literature.

Authors:  Peng Wang; Haitao Zhou; Zhixiang Zhou; Jianwei Liang
Journal:  Onco Targets Ther       Date:  2018-08-13       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.